

## **SYMTUZA® (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) Use of SYMTUZA for Post-Exposure Prophylaxis**

### **SUMMARY**

- SYMTUZA® is not indicated for use in post-exposure prophylaxis (PEP) for the prevention of HIV infection.<sup>1</sup>
- There are no published data evaluating the use of SYMTUZA for PEP.

### **LITERATURE SEARCH**

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® databases (and/or other resources, including internal/external databases) conducted on 25 October 2023 did not identify any relevant literature pertaining to this topic.

### **REFERENCES**

1. Data on File. Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide. Company Core Data Sheet. Janssen Research & Development, LLC. EDMS-ERI-119231875; December 2021.